Prescription Drugs

;

Testimony on the selection of drugs for referral to MD stakeholder council

Mar 20, 2024

We believe Maryland policymakers should focus on those issues that directly impact patients, such as PBM regulation and reform, standard plan designs with reasonable deductibles and nominal copays, and ensuring copay assistance counts. We note that the General Assembly is currently considering HB 879, legislation that would ensure that copay assistance programs will count toward deductibles and out-of-pocket maximums, and the Senate is considering SB 595.

read more

Request for prompt enforcement of prescription drug copay assistance court ruling

Mar 12, 2024

We have long advocated for affordable access to healthcare, including prescription medications.  A recent United States District Court for the District of Columbia ruling pertaining to copay assistance will dramatically help patients afford their medications. We write to urge you to immediately enforce this decision and the rule that it reinstated, issue a bulletin advising insurers that they are obligated to comply with the reinstated rule, and take necessary enforcement actions against insurers that are not in compliance.

read more

Testimony on the IL Health Care Availability and Access Board Act (HB 4472)

Mar 12, 2024

We believe policymakers should focus on those issues that directly impact patients, such as PBM regulation and reform, standard plan designs with reasonable deductibles and nominal copays, and ensuring copay assistance counts. We realize that Illinois has taken many of these steps already, and that Illinois policymakers are advocating for change at the national level, too, but more can be done.

read more

Amicus brief with patient groups on California Rule of Court 8.500(g) on the “duty to innovate”

Mar 11, 2024

Given the importance—and immense cost—of developing new treatments and cures, Amici have a profound interest in ensuring that the law not disincentivize innovation. Amici were accordingly concerned to learn of the new legal duty recognized by the Court of Appeal in this case, which would impose liability on manufacturers of drugs that are undisputedly safe and effective as approved by the FDA itself. The new duty is indifferent to the safety of the existing product, imposing liability if a manufacturer “knew” it could potentially make an even “safer” alternative.

read more

Comments on the NBPP proposed rule for 2025

Jan 9, 2024

We appreciate all you are doing to make healthcare more accessible and affordable for beneficiaries, including several proposals contained in the proposed rule. While we support several of them, this letter focuses on those issues that impact access and affordability of prescription drugs.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest